Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 6/20 | 0.60 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | NEK2 | P51955 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CDK8 | P49336 | 2/20 | 0.42 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | PIR | O00625 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.42 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | STK16 | O75716 | 1/20 | 0.42 |
| ▸ | OXSR1 | O95747 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15600583 | 0.89 | BRAF (0.49) | BRAFMAP2K1CYP3A4NEK2CNR2 | |
| SCHEMBL3509319 | 0.88 | BRAF (0.48) | BRAFMAP2K1CYP3A4NEK2CNR2 | |
| SCHEMBL2354653 | 0.87 | BRAF (0.59) | BRAFMAP2K1CYP3A4NEK2CNR2 | |
| SCHEMBL859194 | 0.86 | BRAF (0.61) | BRAFMAP2K1CYP3A4NEK2CNR2 | |
| SCHEMBL411233 | 0.86 | BRAF (0.61) | BRAFMAP2K1CYP3A4NEK2CNR2 | |
| SCHEMBL859201 | 0.85 | BRAF (0.66) | BRAFMAP2K1CYP3A4NEK2CNR2 | |
| SCHEMBL413729 | 0.84 | BRAF (0.58) | BRAFMAP2K1CYP3A4NEK2CNR2 | |
| SCHEMBL856090 | 0.83 | CYP2C19 (0.53) | BRAFMAP2K1CYP3A4NEK2CYP2C19 | |
| SCHEMBL1085839 | 0.83 | CYP3A4 (0.47) | BRAFMAP2K1CYP3A4NEK2CYP2C19 | |
| SCHEMBL3509981 | 0.82 | MAP2K1 (0.52) | BRAFMAP2K1NEK2CNR2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | claimed |
| EP-1893612-B1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON INC (US) | 2011-08-03 | — | — | EP | claimed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | claimed |
| US-11040027-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2021-06-22 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-9617267-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-2501236-B1 | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer | PLEXXIKON INC (US) | 2017-03-29 | — | — | EP | disclosed |
| EP-3088400-A1 | PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON INC. (US) | 2016-11-02 | — | — | EP | disclosed |
| CN-105906631-A | Compounds and methods for kinase modulation, and indications therefor | 普莱希科公司 | 2016-08-31 | — | — | CN | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| WO-2008079906-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS KINASE MODULATORS | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079903-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS KINASE MODULATORS | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| EP-1893612-A1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007002325-A1 | PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002325-A1 | PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | MAP4K1, MAP4K2, MAP3K1 | BRAF 95/4885MAP2K1 102/4885CYP3A4 4851/4885 |
| US-11040027-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, HNF4A, HGF | BRAF 113/4885MAP2K1 50/4885CYP3A4 1499/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | BRAF 48/4885MAP2K1 153/4885CYP3A4 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.